3Stein JD,Childers D,Gupta S,et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease[J]. JAMA Ophthalmo1,2015,133(3) :290-296. 被引量：1
4Shiber S,Stiebel-Kalish H,Shimon I,et al. Glucocorticoid Regimens for Prevention of Graves" ophthalmopathy progression following radioiodine treatment:systematic review and meta- analysis[J]. Thyroid, 2014,24(10) : 151515- 23. 被引量：1
5Chen DY,Schneider PF,Zhang XS,et al. Changes in graves" ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves" disease from 2 prospective,randomized,open-label, blinded end point studies[J]. Exp Clin Endocrinol Diabetes,2014, 122(1) : 1-6. 被引量：1
6Bahn RS, Burch HB ,Cooper DS,et al. Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J]. Thyroid, 2011,21 : 593-646. 被引量：1
7Bartalena L,Baldeschi L,Dickinson A,et al. European Group on Graves'Orbitopathy (EUGOGO). Consensus statement of the EuropeanGroup onGraves'orbitopathy(EUGOGO) onmanagement of GO[J]. Eur J Endoerinol, 2008,158 : 273-285. 被引量：1
8Mourits MP,Prummel MF,Wiersinga WM,et al. Clinical activity score as a guide in themanagement of patients with Graves' ophthalmopathy[J]. Clin Endocrinol (Oxf), 1997,47:9-14. 被引量：1
9Bartalena L. The dilemma of how to manage Graves' hyperthyroid- ism in patients with associated orbitopathy [J]. J Clin Endocrinol Metab, 2011,96(3) :592-599. 被引量：1
10Tr?isk F,Tallstedt L,Abraham-Nordling M,et al. Thyroid- associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithymid drugs or iodine-131. J Clin Endocrinol Metab, 2009,94(10) : 3700-3707. 被引量：1
